SALE EXTENDED
MarketBeat All Access
Start your 30-day free trial,
then continue your subscription for 50% off.
TODAY ONLY!
Claim Your Discount
×
S&P 500   3,639.66 (-2.80%)
DOW   29,296.79 (-2.11%)
QQQ   269.10 (-3.81%)
AAPL   140.09 (-3.67%)
MSFT   234.24 (-5.09%)
META   133.45 (-4.04%)
GOOGL   98.68 (-2.70%)
AMZN   114.56 (-4.77%)
TSLA   223.07 (-6.32%)
NVDA   120.76 (-8.03%)
NIO   13.76 (-6.84%)
BABA   81.24 (-3.65%)
AMD   58.44 (-13.87%)
T   14.94 (-2.48%)
MU   52.91 (-3.13%)
CGC   2.79 (-25.60%)
F   12.20 (-1.29%)
GE   64.56 (-2.51%)
DIS   97.16 (-2.88%)
AMC   6.53 (-8.29%)
PYPL   90.17 (-4.50%)
PFE   42.32 (-1.79%)
NFLX   224.75 (-6.36%)
S&P 500   3,639.66 (-2.80%)
DOW   29,296.79 (-2.11%)
QQQ   269.10 (-3.81%)
AAPL   140.09 (-3.67%)
MSFT   234.24 (-5.09%)
META   133.45 (-4.04%)
GOOGL   98.68 (-2.70%)
AMZN   114.56 (-4.77%)
TSLA   223.07 (-6.32%)
NVDA   120.76 (-8.03%)
NIO   13.76 (-6.84%)
BABA   81.24 (-3.65%)
AMD   58.44 (-13.87%)
T   14.94 (-2.48%)
MU   52.91 (-3.13%)
CGC   2.79 (-25.60%)
F   12.20 (-1.29%)
GE   64.56 (-2.51%)
DIS   97.16 (-2.88%)
AMC   6.53 (-8.29%)
PYPL   90.17 (-4.50%)
PFE   42.32 (-1.79%)
NFLX   224.75 (-6.36%)
S&P 500   3,639.66 (-2.80%)
DOW   29,296.79 (-2.11%)
QQQ   269.10 (-3.81%)
AAPL   140.09 (-3.67%)
MSFT   234.24 (-5.09%)
META   133.45 (-4.04%)
GOOGL   98.68 (-2.70%)
AMZN   114.56 (-4.77%)
TSLA   223.07 (-6.32%)
NVDA   120.76 (-8.03%)
NIO   13.76 (-6.84%)
BABA   81.24 (-3.65%)
AMD   58.44 (-13.87%)
T   14.94 (-2.48%)
MU   52.91 (-3.13%)
CGC   2.79 (-25.60%)
F   12.20 (-1.29%)
GE   64.56 (-2.51%)
DIS   97.16 (-2.88%)
AMC   6.53 (-8.29%)
PYPL   90.17 (-4.50%)
PFE   42.32 (-1.79%)
NFLX   224.75 (-6.36%)
S&P 500   3,639.66 (-2.80%)
DOW   29,296.79 (-2.11%)
QQQ   269.10 (-3.81%)
AAPL   140.09 (-3.67%)
MSFT   234.24 (-5.09%)
META   133.45 (-4.04%)
GOOGL   98.68 (-2.70%)
AMZN   114.56 (-4.77%)
TSLA   223.07 (-6.32%)
NVDA   120.76 (-8.03%)
NIO   13.76 (-6.84%)
BABA   81.24 (-3.65%)
AMD   58.44 (-13.87%)
T   14.94 (-2.48%)
MU   52.91 (-3.13%)
CGC   2.79 (-25.60%)
F   12.20 (-1.29%)
GE   64.56 (-2.51%)
DIS   97.16 (-2.88%)
AMC   6.53 (-8.29%)
PYPL   90.17 (-4.50%)
PFE   42.32 (-1.79%)
NFLX   224.75 (-6.36%)
NYSE:TAK

Takeda Pharmaceutical - TAK Stock Forecast, Price & News

$13.14
+0.02 (+0.15%)
(As of 10/7/2022 04:33 PM ET)
Add
Compare
Today's Range
$13.04
$13.19
50-Day Range
$12.80
$14.61
52-Week Range
$12.75
$15.36
Volume
3.91 million shs
Average Volume
2.70 million shs
Market Capitalization
$40.74 billion
P/E Ratio
24.79
Dividend Yield
4.19%
Price Target
$24.00

Takeda Pharmaceutical MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.50 Rating Score
Upside/​Downside
83.2% Upside
$24.00 Price Target
Short Interest
Healthy
0.11% of Float Sold Short
Dividend Strength
Weak
Based on Four Factors
Sustainability
N/A
News Sentiment
0.70mentions of Takeda Pharmaceutical in the last 14 days
Based on 4 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
N/A

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.65 out of 5 stars

Medical Sector

116th out of 1,075 stocks

Pharmaceutical Preparations Industry

37th out of 537 stocks

TAK stock logo

About Takeda Pharmaceutical (NYSE:TAK) Stock

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan, the United States, Europe, Canada, Latin America, Russia, rest of Asia, and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab, Alofisel, Dexilant, Natpara, Adynovate/Adynovi, Takhzyro, Livtencity, Elaprase, Replagal, Advate, Vpriv, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Exkivity, Velcade, Leuplin/Enantone, Adcetris, Vyvansese, Trintellix, and Alunbrig brands. Takeda Pharmaceutical Company Limited has out-licensing agreement with Neurocrine Biosciences, Inc.; collaborations and in-licensing agreements with the University of Texas MD Anderson Cancer Center, Arrowhead Pharmaceuticals Inc., and Ovid Therapeutics Inc.; and collaboration with Evox Therapeutics Ltd., as well as a licensing agreement with ProThera Biologics Inc. It also has research collaboration and licensing agreement with Crescendo Biologics, Code Bio, Immusoft, Poseida Therapeutics, Selecta Biosciences, BridGene Biosciences, Skyhawk Therapeutics, and StrideBio; and strategic alliances with Egle Therapeutics SAS; Evotec SE; Neurocrine Biosciences, Inc.; Carmine Therapeutics; KSQ Therapeutics; and Anima Biotech. Takeda Pharmaceutical Company Limited was founded in 1781 and is headquartered in Tokyo, Japan.

Receive TAK Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Takeda Pharmaceutical and its competitors with MarketBeat's FREE daily newsletter.

TAK Stock News Headlines

The Biggest "Missing Ingredient" in the $7 Trillion EV Market
China has owned the graphite market for decades. But the U.S. just added graphite to a list of super-critical minerals... "essential for America's National Defense." Perfect timing for a "made in America" graphite company looking to mine, manufacture, and recycle graphite for the booming electric car market.
Takeda Pharmaceutical (NYSE:TAK) Sees Strong Trading Volume
The Biggest "Missing Ingredient" in the $7 Trillion EV Market
China has owned the graphite market for decades. But the U.S. just added graphite to a list of super-critical minerals... "essential for America's National Defense." Perfect timing for a "made in America" graphite company looking to mine, manufacture, and recycle graphite for the booming electric car market.
Takeda: The Current Price Makes No Sense
Takeda Pharmaceutical Becomes Oversold (TAK)
See More Headlines
Receive TAK Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Takeda Pharmaceutical and its competitors with MarketBeat's FREE daily newsletter.

TAK Company Calendar

Last Earnings
7/28/2022
Today
10/07/2022
Next Earnings (Estimated)
10/27/2022
Fiscal Year End
3/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Employees
47,347
Year Founded
1781

Price Target and Rating

Average Stock Price Forecast
$24.00
High Stock Price Forecast
$24.00
Low Stock Price Forecast
$24.00
Forecasted Upside/Downside
+82.6%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
4 Analysts

Profitability

Net Income
$2.05 billion
Pretax Margin
6.08%

Debt

Sales & Book Value

Annual Sales
$31.79 billion
Cash Flow
$3.49 per share
Book Value
$16.31 per share

Miscellaneous

Outstanding Shares
3,100,722,000
Free Float
3,099,482,000
Market Cap
$40.74 billion
Optionable
Optionable
Beta
0.69

Social Links


Key Executives

  • Mr. Christophe Weber (Age 56)
    Pres, CEO & Representative Director
    Comp: $4.29M
  • Mr. Constantine Saroukos (Age 51)
    CFO & Representative Director
    Comp: $2.56M
  • Dr. Andrew S. Plump (Age 57)
    Pres of R&D and Representative Director
    Comp: $2.43M
  • Dr. Seigo Izumo
    Chair of Management Board
  • Mr. Haruhiko Hirate (Age 65)
    Member of Management Board
  • Salvatore Alesci
    Member of Management Board and Head of R&D Global Science & Biomedical Policy
  • Norimasa Takeda
    Chief Accounting Officer & Corp. Controller
  • Mr. Iwaaki Taniguchi
    Sr. VP of Corp. Fin. & Controlling Department
  • Mr. Gabriele Ricci (Age 44)
    Chief Data & Technology Officer
  • Mr. Christopher David O'Reilly
    Global Head of Investor Relations & Global Fin.













TAK Stock - Frequently Asked Questions

Should I buy or sell Takeda Pharmaceutical stock right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Takeda Pharmaceutical in the last twelve months. There are currently 2 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" TAK shares.
View TAK analyst ratings
or view top-rated stocks.

What is Takeda Pharmaceutical's stock price forecast for 2022?

4 analysts have issued twelve-month price targets for Takeda Pharmaceutical's stock. Their TAK share price forecasts range from $24.00 to $24.00. On average, they expect the company's stock price to reach $24.00 in the next year. This suggests a possible upside of 82.9% from the stock's current price.
View analysts price targets for TAK
or view top-rated stocks among Wall Street analysts.

How have TAK shares performed in 2022?

Takeda Pharmaceutical's stock was trading at $13.63 at the beginning of the year. Since then, TAK stock has decreased by 3.7% and is now trading at $13.12.
View the best growth stocks for 2022 here
.

When is Takeda Pharmaceutical's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, October 27th 2022.
View our TAK earnings forecast
.

How were Takeda Pharmaceutical's earnings last quarter?

Takeda Pharmaceutical Company Limited (NYSE:TAK) issued its earnings results on Thursday, July, 28th. The company reported $0.56 earnings per share for the quarter. The firm earned $7.51 billion during the quarter. Takeda Pharmaceutical had a trailing twelve-month return on equity of 12.41% and a net margin of 5.43%.

Is Takeda Pharmaceutical a good dividend stock?

Takeda Pharmaceutical (NYSE:TAK) pays an annual dividend of $0.55 per share and currently has a dividend yield of 4.09%. TAK has a dividend yield higher than 75% of all dividend-paying stocks, making it a leading dividend payer. The dividend payout ratio is 103.78%. Payout ratios above 75% are not desirable because they may not be sustainable.

What guidance has Takeda Pharmaceutical issued on next quarter's earnings?

Takeda Pharmaceutical updated its FY 2022 earnings guidance on Thursday, August, 4th. The company provided earnings per share (EPS) guidance of $3.74-$3.74 for the period. The company issued revenue guidance of $28.49 billion-$28.49 billion.

What other stocks do shareholders of Takeda Pharmaceutical own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Takeda Pharmaceutical investors own include Cisco Systems (CSCO), Johnson & Johnson (JNJ), Alibaba Group (BABA), Pfizer (PFE), Verizon Communications (VZ), AbbVie (ABBV), CVS Health (CVS), Gilead Sciences (GILD), AT&T (T) and Abbott Laboratories (ABT).

What is Takeda Pharmaceutical's stock symbol?

Takeda Pharmaceutical trades on the New York Stock Exchange (NYSE) under the ticker symbol "TAK."

How do I buy shares of Takeda Pharmaceutical?

Shares of TAK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Takeda Pharmaceutical's stock price today?

One share of TAK stock can currently be purchased for approximately $13.12.

How much money does Takeda Pharmaceutical make?

Takeda Pharmaceutical (NYSE:TAK) has a market capitalization of $40.68 billion and generates $31.79 billion in revenue each year. The company earns $2.05 billion in net income (profit) each year or $0.53 on an earnings per share basis.

How many employees does Takeda Pharmaceutical have?

The company employs 47,347 workers across the globe.

Does Takeda Pharmaceutical have any subsidiaries?
The following companies are subsidiares of Takeda Pharmaceutical: ARIAD Pharmaceuticals, Baxalta Manufacturing S.à r.l., IDM Pharma Inc., Intellikine, Inviragen, LigoCyte Pharmaceuticals, Meritage Pharma Inc., Millennium Pharmaceuticals, Millennium Pharmaceuticals Inc., Nihon Pharmaceutical Co. Ltd., Nycomed Pharma, PvP Biologics, Shire, Shire ViroPharma LLC, Takeda (China) Holdings Co. Ltd., Takeda AS, Takeda Austria GmbH, Takeda Bio Development Center, Takeda California Inc., Takeda Consumer Healthcare Company Limited, Takeda Development Center Americas Inc., Takeda Development Center Asia Pte. Ltd., Takeda Development Centre Europe Ltd., Takeda Distribuidora Ltda., Takeda France S.A.S., Takeda GmbH, Takeda Ireland Limited, Takeda Italia S.p.A., Takeda Pharma A/S, Takeda Pharmaceutical (China) Company Limited, Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals Korea Co. Ltd., Takeda Pharmaceuticals Limited Liability Company, Takeda Pharmaceuticals U.S.A. Inc., Takeda UK Limited, Takeda Vaccines Inc., Takeda Vaccines Pte. Ltd., and TiGenix.
Read More
How can I contact Takeda Pharmaceutical?

Takeda Pharmaceutical's mailing address is 1-1 NIHONBASHI-HONCHO 2-CHOME CHUO-KU, TOKYO M0, 103-8668. The official website for the company is www.takeda.com. The company can be reached via phone at (166) 204-2111 or via fax at 813-3278-2268.

This page (NYSE:TAK) was last updated on 10/7/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access members have access to premium reports, best-in-class portfolio monitoring tools, and our latest stock picks.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies, and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.